Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
BCCIP product was isolated on the basis of its interaction with BRCA2 and p21 proteins.
Showing 10 out of 50 products:
We analyzed the BCCIP protein level in 470 cases of human breast cancer to determine the associations between BCCIP and 53BP1 (Montrer TP53BP1 Anticorps), p53 (Montrer TP53 Anticorps), and subtypes of breast cancer. We further constructed a unique BCCIP knockdown mouse model to determine whether a partial BCCIP deficiency leads to spontaneous breast cancer formation
BCCIPbeta, as a S7 modulator, contributes to the regulation of ribosomal and extraribosomal functions of S7 and has implications in cell growth and tumor development.
this study identifies BCCIP as a novel factor critical for microtubule regulation and explicates a mechanism utilized by BCCIP in tumor suppression.
Expression of BCCIP beta was notably higher in tumor tissues of esophageal squamous cell carcinoma (ESCC) and Eca 109 cells. In vitro studies such as starvation and refeeding assay along with BCCIP beta-shRNA transfection assay demonstrated that BCCIP beta expression promoted proliferation of ESCC cells.
we demonstrate that BCCIPbeta induces a conformational change within the RAD51 (Montrer RAD51 Anticorps) filament that promotes release of ADP to help maintain an active presynaptic filament. Our findings reveal a functional role for BCCIPbeta as a RAD51 (Montrer RAD51 Anticorps) accessory factor in HR.
the existence of both INO80 (Montrer INO80 Anticorps) and YY1 (Montrer YY1 Anticorps) is required for recruiting the INO80 (Montrer INO80 Anticorps)/YY1 (Montrer YY1 Anticorps) complex to BCCIP promoter region. Our findings strongly indicate that BCCIP is a potential target gene of the INO80 (Montrer INO80 Anticorps)/YY1 (Montrer YY1 Anticorps) complex.
The BCCIPbeta, but not BCCIPalpha, interacts with EIF6 (Montrer EIF6 Anticorps) and RPL23 (Montrer RPL17 Anticorps)/UL14 and stabilizes the latter.
Results indicate that BCCIP germ line mutations are unlikely to be a major contributor to familial breast/ovarian cancer risk in our population.
In BRCA2 (Montrer BRCA2 Anticorps), two novel frame shift mutations were identified as 5073-5074delCT and 6866delC.
BRCA2 (Montrer BRCA2 Anticorps) germline mutations appear to have a milder clinical phenotype when compared to non-BRCA2 (Montrer BRCA2 Anticorps) mutations, since survival is higher among breast cancer patients carrying a BRCA2 (Montrer BRCA2 Anticorps) mutation compared to sporadic breast cancers.
BCCIP represents a paradoxical class of modulators for tumorigenesis as a suppressor for initiation but a requisite for progression.
BCCIP and its anti-replication stress functions are essential for normal neural development by maintaining an orderly proliferation of neural progenitors.
these data suggest a unique function of BCCIP, not only in repair of DNA damage, but also in resolving stalled replication forks and prevention of replication stress
This gene product was isolated on the basis of its interaction with BRCA2 and p21 proteins. It is an evolutionarily conserved nuclear protein with multiple interacting domains. The N-terminal half shares moderate homology with regions of calmodulin and M-calpain, suggesting that it may also bind calcium. Functional studies indicate that this protein may be an important cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity via p21. This protein has also been implicated in the regulation of BRCA2 and RAD51 nuclear focus formation, double-strand break-induced homologous recombination, and cell cycle progression. Multiple transcript variants encoding different isoforms have been described for this gene.
BRCA2 and CDKN1A interacting protein
, protein BCCIP homolog
, BRCA2 and CDKN1A-interacting protein
, BRCA2 and Cip1/p21 interacting protein
, cdk inhibitor p21 binding protein
, p21- and CDK-associated protein 1
, protein TOK-1